Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Gastric03
2023-504888-16-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Oct 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 13
01
Overview
Phase 2, open-label trial of trastuzumab deruxtecan in gastric cancer (GC), gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC) (7 arms), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability and Confirmed objective response rate. Planned start Oct 2020; status: authorised.
02
Drugs
trastuzumab deruxtecan
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2023-504888-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504888-16-00.